Pentwater Capital Management’s Trillium Therapeutics Inc. TRIL Stock Holding History

Pentwater Capital Management’s Portfolio TRIL Stock Details TRIL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-3,140,000	Closed	-$55.1M	–	287
2021 Q3	$55.1M	Buy	+3,140,000	New	+$36.7M	0.56%	30

Other funds holding TRIL

Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Pentwater Capital Management's TRIL Position: Q4 2021 in Review

Pentwater Capital Management sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 3,140,000 shares — an estimated $55.1M sold.

Pentwater Capital Management first reported a position in TRIL in Q3 2021 and held it in 1 quarter. The position peaked at $55.1M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

Pentwater Capital Management reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
Pentwater Capital Management sold 3,140,000 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $55.1M.
Pentwater Capital Management first reported a position in Trillium Therapeutics Inc. in Q3 2021 and held it in 1 quarter.
Pentwater Capital Management's Trillium Therapeutics Inc. position peaked at $55.1M in Q3 2021.
2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Pentwater Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.